STOCK TITAN

Alps Group regains Nasdaq minimum bid price compliance

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

Alps Group Inc (ALPS) regained compliance with Nasdaq’s $1.00 minimum bid price requirement for continued listing on The Nasdaq Global Market. The company said its ordinary shares closed at $1.00 per share or greater for 10 consecutive business days, from November 9 to November 20, 2026.

Nasdaq staff had determined that the shares would be subject to delisting after the company failed to regain compliance by the end of its compliance period. Nasdaq later confirmed compliance and closed the matter. Post-consolidation trading began November 9, 2026, following a 1-for-5 share consolidation.

Minimum bid price $1.00 per share Nasdaq continued-listing requirement
Compliance period 10 consecutive business days Closing bid price of $1.00 per share or greater from November 9 to November 20, 2026
Share consolidation 1-for-5 Post-consolidation trading began November 9, 2026
minimum bid price requirement regulatory
"minimum bid price requirement for continued listing"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5450(a)(1) regulatory
"under Nasdaq Listing Rule 5450(a)(1)"
Nasdaq Listing Rule 5450(a)(1) is a continued-listing standard that sets a minimum share price companies must maintain to remain listed on the Nasdaq market—commonly a $1.00 per-share threshold. Investors care because falling below that floor can trigger a compliance review and possible delisting, which is like failing a minimum grade and losing access to the public market; delisting can reduce liquidity, visibility and the ability to raise capital.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Did ALPS regain Nasdaq minimum bid price compliance?

Yes. Alps Group regained compliance after its ordinary shares closed at $1.00 per share or greater for 10 consecutive business days, from November 9 through November 20, 2026. Nasdaq confirmed the matter is closed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 6-K

 

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission File Number: 001-42915

 

 

 

Alps Group Inc

(Registrant’s Name)

 

Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)

No. 1, Jalan 1/68F, Jalan Tun Razak

50400 Kuala Lumpur

Wilayah Persekutuan, Malaysia

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 
 

 

Information Contained in this Form 6-K Report

 

Attached hereto as Exhibit 99.1 is a press release dated November 20, 2026 issued by Alps Group Inc (the “Company”) announcing that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

 

Exhibits

 

Exhibit No.   Description
99.1   Press Release dated November 20, 2026

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Alps Group Inc
     
Date: November 20, 2026 By: /s/ Dr. Seng Kong Tham
  Name: Dr. Seng Kong Tham
  Title: Chief Executive Officer and Director

 

3

 

Exhibit 99.1

 

 

Alps Group Inc Regains Compliance with Nasdaq Minimum Bid Price Requirement

 

KUALA LUMPUR, Malaysia – November 20, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that it has received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market.

 

On May 19, 2026, the Company previously disclosed that, on May 15, 2026, the Company received a letter from Nasdaq notifying the Company that based on the closing bid price of the ordinary shares of the Company for the prior 30 consecutive business days, the Company was not in compliance with the continued listing requirement of Nasdaq under Nasdaq Listing Rules 5450(a)(1), which requires the Company to maintain a minimum bid price of $1.00 per share.

 

On November 9, 2026, the Company’s ordinary shares began trading on a post-consolidation basis following the Company’s previously announced 1-for-5 share consolidation.

 

On November 16, 2026, the Company received a letter from the Nasdaq Listing Qualifications Staff stating that the Company had not regained compliance with Nasdaq Listing Rule 5450(a)(1), which required the listed ordinary shares to maintain a closing bid price of $1.00 per share for 10 consecutive business days, by November 11, 2026, the end of the applicable compliance period, and that the Staff had determined that the Company’s ordinary shares would be subject to delisting.

 

On November 20, 2026, the Nasdaq Listing Qualifications Staff notified the Company that the closing bid price of its ordinary shares had been $1.00 per share or greater for 10 consecutive business days, from November 9, 2026 to November 20, 2026. Accordingly, the Company has regained compliance with the minimum bid price requirement, and Nasdaq has confirmed that the matter is now closed.

 

The notification has no effect on the trading of the Company’s ordinary shares which continue to trade on The Nasdaq Global Market under the symbol “ALPS.”

 

About Alps Group Inc

 

Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development, with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.

 

 
 

 

 

Forward-Looking Statements

 

Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

 

A further list and description of risks and uncertainties can be found in documents filed with or furnished to the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file with or furnish to the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.

 

Investor Relations Contact

 

Alps Group Inc

Investor Relations

Phone: +60 3-2163 1113

Email: investorrelations@alpsmedical.com

 

 

Filing Exhibits & Attachments

2 documents

Keep reading